ReviewEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Teratocarcinosarcoma of the nasal cavity: challenges in the clinico-pathologic perspectives.
Review in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveClinicopathologic illustration of sinonasal teratocarcinosarcoma (SNTCS) in a middle-aged man, highlighting the difficulties and challenges encountered during surgical intervention, histopathologic diagnosis, and its overall management. METHODOLOGY: Case report and literature review.
resultsA 40-year-old man having recurrent epistaxis for three months presented with a dark-colored protruding polypoid nasal mass. Magnetic resonance imaging revealed a large, heterogeneous gadolinium-enhanced infiltrative lesion in the left nasal cavity with a T2-hypointense trans-septal zone. The mass abutted the cribriform plate, lamina papyracea, and septum, involved the inferior and middle turbinates, and blocked the choanae through the nasopharynx. There was profuse hemorrhage when an endoscope-assisted biopsy was attempted. Histopathology from the debulked specimen suggested SNTCS. The diagnosis was confirmed on immunohistochemistry. A metastatic search turned negative. However, at three weeks, the patient returned with a recurrence. A repeat debulking was done, and he was thereafter put on adjuvant chemotherapy. A second recurrence/residual lesion was noted midway through the chemotherapy regimen. However, it resolved after completion of the chemotherapy and subsequent image-guided radiotherapy, and the patient continued to be disease-free till the last follow-up at six weeks postradiotherapy.
conclusionsSNTCS is an extremely aggressive malignancy that is seldom encountered in routine otolaryngology and pathology practice, with only a few reports of SNTCS documented. It is histologically composed of epithelial, mesenchymal, and primitive neuroectodermal elements with areas of undifferentiation. They are notorious for troublesome intra-operative bleeding, making complete surgical excision difficult, and the absence of a tumor-free margin often results in recurrence. Owing to their variegated and heterogeneous tissue composition, histopathologic diagnosis is enormously challenging without a representative tissue sample and immunohistochemistry. In spite of prompt and energetic multimodality treatment, survival rate is dismal.
Indexed as
Identifiers
39724237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.